These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38293023)

  • 1. A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers.
    Dhingra LS; Sangha V; Aminorroaya A; Bryde R; Gaballa A; Ali AH; Mehra N; Krumholz HM; Sen S; Kramer CM; Martinez MW; Desai MY; Oikonomou EK; Khera R
    medRxiv; 2024 Mar; ():. PubMed ID: 38293023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
    Siontis KC; Abreau S; Attia ZI; Barrios JP; Dewland TA; Agarwal P; Balasubramanyam A; Li Y; Lester SJ; Masri A; Wang A; Sehnert AJ; Edelberg JM; Abraham TP; Friedman PA; Olgin JE; Noseworthy PA; Tison GH
    JACC Adv; 2023 Oct; 2(8):. PubMed ID: 38076758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
    Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
    JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
    Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
    Desai MY; Owens A; Geske JB; Wolski K; Naidu SS; Smedira NG; Cremer PC; Schaff H; McErlean E; Sewell C; Li W; Sterling L; Lampl K; Edelberg JM; Sehnert AJ; Nissen SE
    J Am Coll Cardiol; 2022 Jul; 80(2):95-108. PubMed ID: 35798455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Artificial Intelligence to Predict Heart Failure Risk from Single-lead Electrocardiographic Signals: A Multinational Assessment.
    Dhingra LS; Aminorroaya A; Camargos AP; Khunte A; Sangha V; McIntyre D; Chow CK; Asselbergs FW; Brant LC; Barreto SM; Ribeiro ALP; Krumholz HM; Oikonomou EK; Khera R
    medRxiv; 2024 May; ():. PubMed ID: 38854022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem deep learning and logistic regression models to optimize hypertrophic cardiomyopathy detection in routine clinical practice.
    Maanja M; Noseworthy PA; Geske JB; Ackerman MJ; Arruda-Olson AM; Ommen SR; Attia ZI; Friedman PA; Siontis KC
    Cardiovasc Digit Health J; 2022 Dec; 3(6):289-296. PubMed ID: 36589312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial intelligence-guided detection of under-recognized cardiomyopathies on point-of-care cardiac ultrasound: a multi-center study.
    Oikonomou EK; Vaid A; Holste G; Coppi A; McNamara RL; Baloescu C; Krumholz HM; Wang Z; Apakama DJ; Nadkarni GN; Khera R
    medRxiv; 2024 Jun; ():. PubMed ID: 38559021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Marar R; Geske JB; Gersh BJ; Anavekar NS
    Curr Probl Cardiol; 2023 Jan; 48(1):101429. PubMed ID: 36167226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Hypertrophic Cardiomyopathy on Electrocardiographic Images with Deep Learning.
    Sangha V; Dhingra LS; Oikonomou E; Aminorroaya A; Sikand NV; Sen S; Krumholz HM; Khera R
    medRxiv; 2023 Dec; ():. PubMed ID: 38234746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of hypertrophic cardiomyopathy by an artificial intelligence electrocardiogram in children and adolescents.
    Siontis KC; Liu K; Bos JM; Attia ZI; Cohen-Shelly M; Arruda-Olson AM; Zanjirani Farahani N; Friedman PA; Noseworthy PA; Ackerman MJ
    Int J Cardiol; 2021 Oct; 340():42-47. PubMed ID: 34419527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis.
    Rangwala HS; Fatima H; Ali M; Ahmed ST; Rangwala BS; Abbas SR
    Egypt Heart J; 2023 Dec; 75(1):99. PubMed ID: 38041770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scalable Risk Stratification for Heart Failure Using Artificial Intelligence applied to 12-lead Electrocardiographic Images: A Multinational Study.
    Dhingra LS; Aminorroaya A; Sangha V; Camargos AP; Asselbergs FW; Brant LC; Barreto SM; Ribeiro ALP; Krumholz HM; Oikonomou EK; Khera R
    medRxiv; 2024 Apr; ():. PubMed ID: 38633808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
    Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
    Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
    Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
    J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.